Paraganglioma

Paraganglioma is a neuroendocrine tumor arising from the extra-adrenal paraganglia, aggregates of neural crest-derived cells distributed along the sympathetic and parasympathetic axes from the skull base to the pelvic floor. Together with pheochromocytoma, it forms the spectrum of chromaffin and nonchromaffin paraganglionic tumors; in clinical practice, however, the extra-adrenal location affects presentation, diagnostic work-up, choice of functional imaging and surgical strategy. A substantial proportion of paragangliomas arising from the sympathetic compartment produce catecholamines, whereas many parasympathetic lesions, particularly those in the head and neck, are nonsecreting and present as slow-growing masses.

The medical relevance of paraganglioma derives not only from its rarity, but from the combination of three elements: the risk of acute cardiovascular events in secreting forms, the difficulty of early diagnosis in nonsecreting forms and a high rate of genetic predisposition, which requires a structured approach to counseling, family screening and follow-up. Moreover, as with chromaffin tumors in general, metastatic potential cannot be determined with certainty on histology alone, and management must be based on a longitudinal surveillance strategy tailored to the patient’s individual risk.

The epidemiology of paragangliomas is strongly influenced by anatomical location and secretory profile. Head and neck forms, which are often parasympathetic and nonsecreting, are typically identified because of mass effect or as incidental findings on imaging performed for other reasons. Thoracoabdominal and pelvic forms, which are more often sympathetic, may instead present with adrenergic symptoms and blood pressure instability. In practical terms, the distribution observed in clinical centers depends on how frequently biochemical testing is performed for secondary hypertension and how often neck or abdominal imaging is obtained for other indications.

Age at presentation is variable. Young age at onset, multifocality and bilaterality, as well as the presence of multiple lesions along the paraganglionic axis, increase the likelihood of hereditary predisposition. In contemporary series, the proportion of patients carrying a pathogenic germline variant is sufficiently high to make genetics a primary epidemiological determinant rather than an ancillary consideration. This observation is particularly important in head and neck paragangliomas, in which family history and variants in succinate dehydrogenase genes are clinically relevant for defining the risk of multifocality and recurrence over time.

Nongenetic risk factors are less clearly defined than in other solid tumors, but certain clinical settings increase the likelihood of diagnosis or the clinical impact of disease. Resistant hypertension or paroxysmal adrenergic episodes increase the pretest probability of a secreting sympathetic paraganglioma. Conversely, in nonsecreting tumors of the neck, the practical “risk factor” is often the availability of imaging and the slow growth that allows the lesion to become clinically palpable or symptomatic because of compression of neural and vascular structures.

Patient vulnerability critically depends on cardiovascular and neurological comorbidities. In secreting forms, ischemic heart disease, heart failure, arrhythmias, cerebrovascular disease and frailty increase the likelihood of acute catecholamine-triggered complications. In head and neck forms, proximity to cranial nerves and major vessels makes the risk of neurological deficits due to compression or treatment clinically relevant and influences the choice among surgery, radiotherapy and active surveillance.

Finally, the clinical epidemiology of paragangliomas is influenced by surveillance programs for carriers of predisposing genetic variants. In these settings, diagnosis may occur at a subclinical stage, when lesions are small and potentially treatable with lower morbidity. This shifts the paradigm from late identification because of complications or mass effect to prevention through structured follow-up pathways, which have become a central component of modern clinical practice.

Paragangliomas arise from paraganglionic cells associated with the autonomic nervous system. Sympathetic paraganglia, located along the sympathetic chain and in para-aortic sites, more often have chromaffin properties and may synthesize catecholamines. Parasympathetic paraganglia, located mainly in the head and neck, are more commonly nonsecreting and behave as slow-growing tumors whose symptoms result from mass effect. This anatomical and functional distinction is the first level of etiopathogenetic understanding, because the clinical profile and diagnostic tests depend on both location and secretory biology.

From an etiological perspective, genetic predisposition is a dominant factor. A large proportion of paragangliomas are associated with pathogenic germline variants in genes involved in mitochondrial metabolism and the cellular response to hypoxia, particularly abnormalities affecting the succinate dehydrogenase complex. These variants may cause metabolic remodeling with accumulation of metabolites that act as “pseudohypoxic” signals, promoting proangiogenic and proliferative transcriptional programs. The resulting biological environment favors tumor growth and may also alter the propensity for multifocality and metastasis.

The pathophysiology of secreting forms is mediated by catecholamines and their interaction with adrenergic receptors. Norepinephrine causes vasoconstriction and increased peripheral resistance through alpha-adrenergic receptors, whereas the adrenergic component may amplify tachycardia and arrhythmias through beta receptors. Secreting sympathetic paragangliomas may produce a more continuous or more intermittent catecholaminergic signal; in either case, blood pressure instability and cardiac vulnerability depend on vascular and myocardial reserve, as well as precipitating factors such as stress, procedures and medications.

Nonsecreting forms, typically located in the head and neck, have a different pathophysiology dominated by mass effect. Slow growth may compress cranial nerves and vascular structures, causing dysphonia, dysphagia, impaired tongue movement or sensory abnormalities, depending on the location. Proximity to the carotid bifurcation, jugular foramen and parapharyngeal structures makes the anatomical relationship a primary clinical and therapeutic determinant, because the risks of treatment must be balanced against the risks of progression.

A cross-cutting concept is that metastatic potential cannot be determined with certainty by histological assessment alone. Biological prognosis is derived from the integration of location, size, behavior over time, genetic profile and the presence of metastases in sites lacking normal paraganglionic tissue. This perspective makes prolonged follow-up necessary, particularly in hereditary settings, and explains why management is directed not only at treating the current lesion but also at preventing and detecting new manifestations of disease at an early stage.

The clinical presentation of paraganglioma varies substantially according to location and secretion. In secreting sympathetic forms, patients may report paroxysmal episodes of palpitations, tremor, sweating, pallor and headache, often associated with sudden increases in blood pressure. In other cases, the presentation is persistent or resistant hypertension, with subtler symptoms and a clinical history that may be interpreted as essential hypertension if the pattern of instability and autonomic symptoms is not recognized.

The medical history may reveal exercise intolerance, dyspnea, chest pain, somatic anxiety and sleep disturbances. Catecholamines also alter glucose metabolism, and some patients report worsening glycemic control or a new diagnosis of hyperglycemia, particularly when secretion is sustained. Symptom variability is a key feature: between episodes, patients may feel relatively well, with nearly normal vital signs, which contributes to diagnostic delays.

In nonsecreting head and neck forms, presentation is often dominated by mass effect. Patients may notice a lateral neck swelling, a foreign-body sensation, dysphonia or dysphagia. Compression or infiltration of cranial nerves may cause focal deficits, such as dysphonia due to vagal nerve involvement or impaired tongue mobility. In some cases, onset is asymptomatic and the lesion is identified incidentally on imaging of the neck or skull base.

On physical examination, secreting forms may be associated with hypertension, tachycardia or orthostatic hypotension, which should be actively assessed because of its diagnostic and therapeutic implications. In neck tumors, palpation may reveal a pulsatile or tender mass, but physical examination is insufficient to define the precise location and anatomical relationships, which require dedicated imaging. In patients with cardiovascular symptoms, examination may show signs of heart failure or arrhythmias, increasing the urgency of a targeted endocrine assessment.

An important clinical point is that some presentations are indirect. Paraganglioma may manifest as catecholamine-induced cardiomyopathy, complex arrhythmias or hypertensive crises during procedures or anesthesia in an undiagnosed patient. Conversely, a head and neck paraganglioma may become clinically evident only after causing neurological deficits or when treatment carries substantial functional risks. Clinical findings must therefore be interpreted through an integrated approach linking location, secretion and patient vulnerability.

Paraganglioma should be suspected when compatible adrenergic symptoms are associated with blood pressure instability or resistant hypertension, particularly when episodes are recurrent and unexplained by other causes. Severe headache, palpitations and sweating during paroxysmal episodes accompanied by sudden blood pressure elevations suggest a catecholamine-secreting chromaffin neoplasm. However, the absence of the complete triad does not exclude the diagnosis, and suspicion should remain high in patients with partial symptoms or atypical presentations, especially when they are young or have a family history of neuroendocrine tumors.

A crucial setting is the presence of an extra-adrenal mass identified on imaging. Para-aortic, paravertebral, pelvic or thoracic lesions require targeted assessment because the risk of a catecholaminergic crisis during invasive procedures or biopsy is real in secreting forms. Similarly, a head and neck mass located at a typical site of parasympathetic paraganglia should raise consideration of this diagnosis even in the absence of hypertension or adrenergic symptoms, because many such lesions are nonsecreting.

Suspicion should be particularly strong in confirmed or suspected carriers of a genetic predisposition, as well as in patients with multiple tumors, bilateral disease, recurrences or associated endocrine neoplasms. In these settings, even mild symptoms or small radiological findings justify a structured diagnostic work-up, because early diagnosis reduces morbidity and allows more conservative treatment strategies.

Finally, suspicion should include cardiovascular and neurological scenarios. New-onset arrhythmias, sudden cardiomyopathy, episodes of severe perioperative hypertension or focal neurological symptoms associated with a neck mass are situations in which paraganglioma should be considered. Once the suspicion has been raised, the diagnostic sequence should be rapid and orderly, because prevention of acute complications and planning of safe treatment depend on timely identification of the secretory profile and tumor location.

The diagnosis of paraganglioma is based on a pathway integrating biochemical demonstration of catecholamine hypersecretion when present, anatomical localization and functional characterization in selected cases. In suspected secreting forms, first-line tests are measurement of free plasma metanephrines or fractionated urinary metanephrines, because metanephrines are robust markers of catecholamine production and provide high diagnostic sensitivity. Proper preanalytical standardization is essential to reduce false-positive results related to stress, uncontrolled posture, interfering medications and acute conditions.

In nonsecreting head and neck forms, biochemical testing may be negative, and the diagnostic pathway focuses on structural imaging and, when appropriate, functional imaging to define disease extent, multifocality and biological behavior. Anatomical localization depends on the suspected site: abdominal and chest CT or MRI are useful for lesions of the sympathetic compartment, whereas MRI of the neck and skull base is often central for parasympathetic forms. In both cases, definition of the anatomical relationships with vessels and nerves is essential for planning safe treatment.

Diagnostic assessment of paraganglioma

• Biochemical assessment in suspected secreting forms: free plasma metanephrines or fractionated urinary metanephrines, with strict control of preanalytical conditions and potential interferences.
• Anatomical localization: MRI or CT according to the site, with definition of relationships to neurovascular structures and assessment of multifocality.
• Functional imaging when indicated: dedicated techniques for staging, detection of multiple lesions, recurrence or metastatic disease, and guidance of therapeutic choices in selected cases.
• Genetic evaluation: counseling and genetic testing considered integral components of the diagnostic pathway, with implications for follow-up and family screening.

The choice of functional imaging depends on the clinical context, suspicion of multifocal or metastatic disease and the biological profile suggested by location and genetics. In patients with a high probability of multiple lesions or with equivocal findings on anatomical imaging, functional imaging improves sensitivity and specificity for mapping the full extent of disease. This is particularly important in paragangliomas associated with hereditary predisposition, in which multiple lesions along the paraganglionic axis may be small and not apparent on conventional imaging.

A decisive diagnostic consideration is the avoidance of high-risk procedures in secreting forms. When biochemical or clinical suspicion is present, invasive procedures involving the mass should be planned only after the catecholamine profile has been defined and appropriate preparation instituted, because manipulation may precipitate hypertensive crises and arrhythmias. Diagnosis therefore involves not only identifying a lesion, but also constructing a pathway that makes treatment safe.

Finally, diagnosis should include assessment of clinical severity and complications. ECG and, when appropriate, cardiological evaluation are indicated in secreting forms or in patients with cardiovascular symptoms. When features suggest a genetic predisposition, the diagnostic process extends beyond the individual patient, because genetic characterization guides family screening and surveillance for other associated tumor manifestations.

The classification of paragangliomas is useful when it links location, secretion and risk. A first distinction separates paragangliomas of the sympathetic compartment from those of the parasympathetic compartment. The former are more often abdominal, thoracic or pelvic and are more likely to secrete catecholamines; the latter are typically located in the head and neck and are frequently nonsecreting. This difference determines distinct diagnostic pathways, because biochemical testing is often central in sympathetic forms, whereas imaging and assessment of anatomical relationships guide the strategy for neck tumors.

A second dimension concerns the secretory profile. Even among secreting forms, there are differences in the predominance of norepinephrine, epinephrine or, in specific settings, dopamine and its metabolites, with consequences for symptoms and cardiovascular risk. Forms associated with blood pressure instability and tachyarrhythmias have a greater clinical impact and require more intensive preparation before any definitive treatment. In this sense, severity derives from the risk of acute events and the patient’s vulnerability.

Location also affects oncological risk and therapeutic options. Extra-adrenal lesions may be more difficult to resect completely because of their proximity to major vessels or neural structures, and the choice among surgery, radiotherapy and surveillance must consider potential functional morbidity. In head and neck paragangliomas, balancing local control against preservation of cranial nerve function is often the central issue in clinical decision-making, particularly when growth is slow and the patient has few symptoms.

The hereditary dimension represents an additional level of classification. The presence of a genetic predisposition modifies the likelihood of multifocality, recurrence and new lesions over time. This makes “severity” a concept that is not limited to the current event, but extends to future risk and the need for continuous surveillance. In this setting, management of paraganglioma becomes a long-term pathway in which treatment of the current lesion is integrated with prevention and early diagnosis of subsequent manifestations.

Finally, classification must recognize that malignancy is defined by the presence of metastases in sites lacking normal paraganglionic tissue. Because biological prognosis cannot always be predicted at the time of initial diagnosis, risk stratification requires an integrated approach combining location, size, genetics, behavior and serial imaging findings to guide the intensity and duration of follow-up.

Treatment of paraganglioma depends on location, secretion, extent and the risk of morbidity associated with the available therapeutic options. In secreting forms, definitive treatment is often surgical, but any intervention must be preceded by careful pharmacological preparation with alpha-adrenergic blockade and optimization of intravascular volume to reduce the risk of an intraoperative catecholaminergic crisis and post-resection hypotension. After adequate alpha-blockade, a beta-blocker may be used when necessary to control tachycardia and arrhythmias, while isolated beta-blockade must be avoided because it may worsen vasoconstriction.

Surgery for extra-adrenal paragangliomas may be more complex than adrenal surgery because of proximity to major vessels, nerve plexuses and deep retroperitoneal structures. The objective is complete resection whenever possible, but the strategy must account for safety and the likelihood of residual disease. For tumors close to critical structures, planning in experienced centers and integration with functional imaging may reduce operative risk and improve the likelihood of radical resection. In multifocal disease or hereditary settings, the strategy may require balancing disease control against functional preservation.

In head and neck paragangliomas, which are often nonsecreting and slow-growing, treatment may include surgery, radiotherapy or active surveillance depending on size, growth, symptoms and the risk of neurological deficits. Surgery may provide local control but carries risks of injury to cranial nerves and vascular structures; radiotherapy may be considered for local control with a potential reduction in surgical risk in specific settings. Surveillance is an option for selected patients with small, stable lesions when the risks of treatment exceed those of progression.

In metastatic or unresectable disease, management is multimodal and includes control of catecholamine-related symptoms, systemic therapies and, in selected cases, radiometabolic approaches guided by functional imaging. The objectives are to reduce secretory activity, control tumor growth and improve quality of life. Therapeutic selection depends on the location of metastases, rate of progression, biological profile and availability of options at specialist centers.

In all forms, management of comorbidities is an integral part of treatment. Blood pressure control, prevention and treatment of arrhythmias, cardiological optimization and management of glucose metabolism reduce the risk of events and improve tolerability of definitive therapies. Effective treatment is treatment that makes the intervention or chosen strategy safe and establishes from the outset a follow-up plan consistent with the patient’s genetic and biological risk.

Follow-up of paraganglioma is essential because of the risk of recurrence, new lesions and metastases, with probability strongly influenced by location and genetics. Surveillance should be structured as a long-term pathway, particularly in patients with hereditary predisposition or multifocal lesions. The first objective is to confirm treatment effectiveness by documenting biochemical normalization in secreting forms and radiological stability in nonsecreting forms or in tumors managed with nonsurgical strategies.

In secreting forms, biochemical monitoring is based on metanephrines measured at intervals tailored to risk. Methodological consistency over time facilitates longitudinal comparisons and reduces interpretive uncertainty. In the presence of borderline results, preanalytical conditions and potential interferences should be considered, with repeat testing under optimal conditions when necessary, but without excessive delay when clinical findings and imaging suggest recurrent disease.

Radiological follow-up depends on the risk profile and tumor location. In head and neck paragangliomas, surveillance may require periodic imaging of the neck and skull base to assess growth and anatomical relationships, particularly when an observational strategy is adopted or after radiotherapy. In paragangliomas of the sympathetic compartment, abdominal and chest imaging may be indicated according to the risk of multifocality or metastases. Functional imaging may be repeated in selected settings, particularly when multiple lesions are suspected or when anatomical imaging does not explain a biochemical signal of recurrent disease.

The genetic component profoundly modifies follow-up. In carriers of predisposing variants, monitoring is not limited to the original site but includes the possibility of new lesions along the paraganglionic axis and, in specific settings, other associated neoplasms. Genetic counseling and assessment of relatives when indicated are integral components of care, because prevention of acute complications also depends on early identification of tumors in at-risk individuals.

Finally, follow-up should include assessment of cardiovascular and neurological consequences. In secreting forms, blood pressure and arrhythmic burden may improve after treatment, but abnormalities may persist if hypertension was longstanding or if target-organ damage is present. In head and neck paragangliomas, functional surveillance of cranial nerves and swallowing may be relevant, because the objective is not only disease control but also preservation of quality of life.

The prognosis of paraganglioma depends on location, secretory profile, extent and genetic predisposition. In effectively treated localized tumors, outcomes are often favorable, with control of symptoms in secreting forms and local stability in nonsecreting forms. Prognosis must nevertheless be considered from a long-term perspective, because recurrence and new lesions may occur, particularly in hereditary settings. The presence of metastases is the principal determinant of an unfavorable prognosis and requires multimodal strategies and intensive surveillance.

The most feared complications in secreting forms are cardiovascular. Hypertensive crises may cause stroke, myocardial ischemia, malignant arrhythmias and heart failure. Catecholamine exposure may induce catecholamine-induced cardiomyopathy and electrical instability, with potential recovery after control of the secretory source but a risk of sequelae if ischemic events have occurred or exposure has been prolonged. Glucose metabolism may also be impaired, with hyperglycemia that tends to improve after treatment but may persist when insulin resistance or pre-existing diabetes is present.

In head and neck forms, complications are often related to compression and treatment. Tumor growth may cause cranial nerve dysfunction with dysphonia, dysphagia and focal neurological deficits. Definitive therapies may also carry substantial functional risks, which is why therapeutic selection must balance local control against neurological preservation. In selected patients, surveillance may reduce the risk of iatrogenic injury when growth is slow and symptoms are minimal, but it requires rigorous follow-up to detect clinically relevant progression.

Perioperative complications in secreting forms are a critical issue. Without diagnosis and preparation, tumor manipulation and anesthesia may trigger catecholaminergic crises. Even with adequate preparation, post-resection hypotension may occur because of volume depletion and abrupt withdrawal of catecholaminergic stimulation, making expert anesthetic and postoperative management necessary. Prognosis is therefore closely linked to the quality of the preoperative pathway and management in experienced centers.

Overall, paraganglioma is often controllable and sometimes curable, but it requires specialist management integrating biochemical and radiological diagnosis, genetic evaluation and long-term follow-up. The best prognosis is achieved through early diagnosis, personalized therapeutic planning and risk-adapted surveillance, with particular attention to hereditary cases and extra-adrenal tumors that are anatomically complex.